M7T Stock Overview
Mach7 Technologies Limited provides enterprise imaging data sharing, storage, and interoperability for healthcare enterprises worldwide.
No risks detected for M7T from our risk checks.
Mach7 Technologies Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.62|
|52 Week High||AU$1.10|
|52 Week Low||AU$0.51|
|1 Month Change||-15.07%|
|3 Month Change||-16.22%|
|1 Year Change||-41.78%|
|3 Year Change||90.77%|
|5 Year Change||244.44%|
|Change since IPO||-1.59%|
Recent News & Updates
Is Mach7 Technologies Limited (ASX:M7T) Potentially Undervalued?
While Mach7 Technologies Limited ( ASX:M7T ) might not be the most widely known stock at the moment, it saw a...
|M7T||AU Healthcare Services||AU Market|
Return vs Industry: M7T underperformed the Australian Healthcare Services industry which returned -17.1% over the past year.
Return vs Market: M7T underperformed the Australian Market which returned 1.5% over the past year.
|M7T Average Weekly Movement||7.4%|
|Healthcare Services Industry Average Movement||9.2%|
|Market Average Movement||9.5%|
|10% most volatile stocks in AU Market||16.6%|
|10% least volatile stocks in AU Market||4.3%|
Stable Share Price: M7T is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: M7T's weekly volatility (7%) has been stable over the past year.
About the Company
Mach7 Technologies Limited provides enterprise imaging data sharing, storage, and interoperability for healthcare enterprises worldwide. It operates through two segments, Sale of Software Licenses and Rendering of Professional Services. The Company offers enterprise diagnostic viewing solutions that include eUnity Enterprise Viewer and eUnity Diagnostic Viewer.
Mach7 Technologies Fundamentals Summary
|M7T fundamental statistics|
Is M7T overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|M7T income statement (TTM)|
|Cost of Revenue||AU$17.76m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.011|
|Net Profit Margin||-9.90%|
How did M7T perform over the long term?See historical performance and comparison
How is Mach7 Technologies forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: M7T is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.8%).
Earnings vs Market: M7T is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: M7T's is expected to become profitable in the next 3 years.
Revenue vs Market: M7T's revenue (10.6% per year) is forecast to grow faster than the Australian market (4.8% per year).
High Growth Revenue: M7T's revenue (10.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: M7T is forecast to be unprofitable in 3 years.
How has Mach7 Technologies performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: M7T is currently unprofitable.
Growing Profit Margin: M7T is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: M7T is unprofitable, but has reduced losses over the past 5 years at a rate of 31.2% per year.
Accelerating Growth: Unable to compare M7T's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: M7T is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (10.6%).
Return on Equity
High ROE: M7T has a negative Return on Equity (-4.37%), as it is currently unprofitable.
How is Mach7 Technologies's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: M7T's short term assets (A$29.8M) exceed its short term liabilities (A$8.3M).
Long Term Liabilities: M7T's short term assets (A$29.8M) exceed its long term liabilities (A$10.5M).
Debt to Equity History and Analysis
Debt Level: M7T is debt free.
Reducing Debt: M7T has no debt compared to 5 years ago when its debt to equity ratio was 0.2%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable M7T has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: M7T is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 53.1% per year.
What is Mach7 Technologies's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate M7T's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate M7T's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if M7T's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if M7T's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as M7T has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Michael Lampron, also known as Mike, serves as Managing Director and Director of Mach7 Technologies Limited since June 24, 2019 and also serves as Chief Executive Officer. With over 20 years ofexperie...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD445.03K) is above average for companies of similar size in the Australian market ($USD288.42K).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
Experienced Management: M7T's management team is not considered experienced ( 0.6 years average tenure), which suggests a new team.
Experienced Board: M7T's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: M7T insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Mach7 Technologies Limited's employee growth, exchange listings and data sources
- Name: Mach7 Technologies Limited
- Ticker: M7T
- Exchange: ASX
- Founded: 2007
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: AU$148.072m
- Shares outstanding: 238.83m
- Website: https://www.mach7t.com
Number of Employees
- Mach7 Technologies Limited
- 120 Kimball Avenue
- Suite 210
- South Burlington
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/22 00:00|
|End of Day Share Price||2022/05/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.